SCHEMBL7174607

SCHEMBL7174607

COc1cc(OC)c(C(=O)C(CCP=O)c2ccccc2)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 6/20 0.41
MEN1 O00255 5/20 0.41
MAPT P10636 2/20 0.40
CYP3A4 P08684 2/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
TP53 P04637 1/20 0.40
ATM Q13315 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PTPN1 P18031 1/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HIF1A Q16665 1/20 0.39
TACR1 P25103 1/20 0.38
USP2 O75604 1/20 0.38
MAPK1 P28482 1/20 0.38
MTNR1B P49286 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7190445 0.93 TDP1 (0.42) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL7183259 0.92 TDP1 (0.42) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL7174905 0.88 CA12 (0.45) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL7180696 0.87 TDP1 (0.46) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL7177669 0.81 TDP1 (0.43) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL7185428 0.81 CA12 (0.43) KMT2AMEN1LMNAALDH1A1
SCHEMBL7186925 0.81 FABP4 (0.42) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL7175427 0.80 CA12 (0.42) KMT2AMEN1LMNAALDH1A1
SCHEMBL7183576 0.78 KMT2A (0.44) TDP1L3MBTL1KMT2AMEN1MAPT
SCHEMBL7182287 0.76 SLC6A2 (0.36) TDP1L3MBTL1KMT2AMEN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TDP1 4234/4885L3MBTL1 302/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TDP1 4275/4885L3MBTL1 126/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.